Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Бремя COVID-19 в гетерогенной популяции иммунокомпрометированных пациентов – реалии постпандемии - Журнал Терапевтический архив №8 Вопросы лечения 2023
Бремя COVID-19 в гетерогенной популяции иммунокомпрометированных пациентов – реалии постпандемии
Авдеев С.Н., Чуланов В.П., Алексеева Е.И., Алешина О.А., Березников А.В., Котенко О.Н., Лила А.М., Мутовина З.Ю., Паровичникова Е.Н., Фомина Д.С., Фролова Н.Ф., Шевченко А.О. Бремя COVID-19 в гетерогенной популяции иммунокомпрометированных пациентов – реалии постпандемии. Терапевтический архив. 2023;95(8):722–729. DOI: 10.26442/00403660.2023.08.202391
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
3 июля 2023 г. в Москве состоялся междисциплинарный Совет экспертов с ведущими специалистами в области пульмонологии, ревматологии, гематологии, онкологии, нефрологии, аллергологии-иммунологии, трансплантологии и инфекционных болезней. Целью заседания было обсуждение текущей клинико-эпидемиологической ситуации, связанной с COVID-19, актуальности профилактики заболевания для пациентов из групп высокого риска. Экспертами рассмотрены следующие вопросы: 1) бремя заболевания COVID-19 в 2023 г. для пациентов со сниженным иммунным статусом в различных терапевтических областях; 2) место пассивной иммунизации моноклональными антителами как метода профилактики COVID-19 среди иммунокомпрометированных пациентов; 3) необходимые условия для внедрения пассивной иммунизации иммунокомпрометированных пациентов в рутинную практику.
Ключевые слова: COVID-19, иммунитет, пассивная иммунизация, моноклональные антитела
Keywords: COVID-19, immunity, passive immunization, monoclonal antibodies
Ключевые слова: COVID-19, иммунитет, пассивная иммунизация, моноклональные антитела
________________________________________________
Keywords: COVID-19, immunity, passive immunization, monoclonal antibodies
Полный текст
Список литературы
1. WHO Director-General's opening remarks at the media briefing – 5 May 2023. Available at: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-m.... Accessed: 12.07.2023.
2. Стопкоронавирус.рф – официальный интернет-ресурс для информирования населения по вопросам коронавируса (COVID-19). Режим доступа: https://стопкоронавирус.рф/ Ссылка активна на 12.07.2023 [Stopcoronavirus.rf – official Internet resource for informing the population about coronavirus (COVID-19). Available at: https://стопкоронавирус.рф/ Accessed: 12.07.2023 (in Russian)].
3. Information for Persons Who Are Immunocompromised Regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages. Available at: https://www.cdc.gov/mmwr/volumes/72/wr/mm7205e3.htm. Accessed: 12.07.2023.
4. Nussenblatt V, Roder AE, Das S, et al. Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion. medRxiv [Preprint]. 2021:2021.10.02.21264267. DOI:10.1101/2021.10.02.21264267
5. Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592(7853):277-82. DOI:10.1038/s41586-021-03291-y
6. Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New Engl J Med. 2021;385(13):1244-6. DOI:10.1056/NEJMc2111462
7. Cheung MW, Dayam RM, Shapiro JR, et al. Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in immunocompromised adult patients. J Immunol. 2023;211(3):351-64. DOI:10.4049/jimmunol.2300190
8. Turtle L, Thorpe M, Drake TM, et al. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the who ISARIC CCP-UK prospective cohort study. PLoS Med. 2023;20(1):e1004086. DOI:10.1371/journal.pmed.1004086
9. Singson JRC, Kirley PD, Pham H, et al. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19 – COVID-NET, 10 states, March 2020 – February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(27):878. DOI:10.15585/mmwr.mm7127a3
10. Brosh-Nissimov T, Hussein K, Wiener-Well Y, et al. Hospitalized patients with severe coronavirus disease 2019 during the omicron wave in Israel: Benefits of a fourth vaccine dose. Clin Infect Dis. 2023;76(3):e234-9. DOI:10.1093/cid/ciac501
11. Всероссийский союз пациентов. Анализ влияния коронавирусной инфекции на людей с ослабленным иммунитетом. Режим доступа: https://vspru.ru/news/2023/04/10042023-gruppa-riska-silno-riskuet. Ссылка активна на 09.06.2023 [All-Russian Union of Patients. Analysis of the impact of coronavirus infection on immunocompromised people. Available at: https://vspru.ru/news/2023/04/10042023-gruppa-riska-silno-riskuet. Accessed: 09.06.2023 (in Russian)].
12. Насонов Е.Л., Лила А.М., Мазуров В.И., и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021;59(3):239-54 [Nasonov EL, Lila AM, Mazurov VI, et al. Coronavirus disease 2019 (COVID-19) and immunoinflammatory rheumatic diseases. Recommendations of the All-Russian public organization “Association of Rheumatologists of Russia”. Scientific and Practical Rheumatology. 2021;59(3):239-54 (in Russian)]. DOI:10.47360/1995-4484-2021-239-254
13. Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(10):1255-65. DOI:10.1136/annrheumdis-2021-221244
14. Saleem B, Ross RL, Bissell LA, et al. Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses. RMD Open. 2022;8(1):e002050. DOI:10.1136/rmdopen-2021-002050
15. Khemiri H, Ayouni K, Triki H, et al. SARS-CoV-2 infection in pediatric population before and during the Delta (B. 1.617. 2) and Omicron (B. 1.1. 529) variants era. Virol J.
2022;19(1):1-16. DOI:10.1186/s12985-022-01873-4
16. Leidman E, Duca LM, Omura JD, et al. COVID-19 trends among persons aged 0–24 years – United States, March 1 – December 12, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(3):88. DOI:10.15585/mmwr.mm7003e1
17. Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr. 2021;180(7):2019-34. DOI:10.1007/s00431-021-03993-5
18. Brough HA, Kalayci O, Sediva A, et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – the 2020 COVID-19 pandemic: a statement from the EAACI-section on pediatrics. Pediatr Allergy Immunol. 2020;31(5):442-8. DOI:10.1111/pai.13262
19. Jansen MHA, Rondaan C, Legger GE, et al. EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Ann Rheum Dis. 2023;82(1):35-47. DOI:10.1136/annrheumdis-2022-222574
20. Kato M. New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors. Immunol Med. 2020;43(2):72-8. DOI:10.1080/25785826.2020.1751908
21. Криулин И.А., Алексеева Е.И., Дворяковская Т.М., и др. Гемофагоцитарный синдром: механизмы развития, клинические проявления, терапевтические технологии. Вопросы практической педиатрии. 2021;16(6):94-102 [Kriulin IA, Alekseeva EI, Dvoryakovskaya TM, et al. Hemophagocytic syndrome: mechanisms of development, clinical manifestations, therapeutic technologies. Clinical Practice in Pediatrics. 2021;16(6):94-102 (in Russian)]. DOI:10.20953/1817-7646-2021-6-94-102
22. Шилов Е.М., Есаян А.М., Шилова М.М., и др. Возможная структура стадий хронической болезни почек в Российской Федерации. Клиническая нефрология. 2021;4:6-7 [Shilov EM, Esayan AM, Shilova MM, et al. Possible structure of stages of chronic kidney disease in the Russian Federation. Clinical Nephrology. 2021;4:6-7 (in Russian)]. DOI:10.18565/nephrology.2021.4.6-7
23. Шилов Е.М., Шилова М.М., Румянцева Е.И., и др. Состояние нефрологической службы в Российской Федерации: заместительная почечная терапия в период с 2017 по 2021 г. Клиническая нефрология. 2021;1:6-15 [Shilov EM, Shilova MM, Rumyantseva EI, et al. The state of the nephrological service in the Russian Federation: renal replacement therapy in the period from 2017 to 2021. Clinical Nephrology. 2021;1:6‑15 (in Russian)]. DOI:10.18565/nephrology.2022.1.6-15
24. Котенко О.Н., Васина Н.В., Марченкова Л.В., и др. Состояние заместительной терапии хронической почечной недостаточности в Москве в 2015–2020 гг. Клиническая нефрология. 2021;1:13-9 [Kotenko ON, Vasina NV, Marchenkova LV, et al. State of replacement therapy for chronic renal failure in Moscow in 2015–2020. Clinical Nephrology.
2021;1:13-9 (in Russian)]. DOI:10.18565/nephrology.2021.1.13-19
25. Батюшин М.М., Трубникова М.А., Тарловская Е.И., и др. Влияние поражения почек на течение и прогноз при инфекции COVID-19 по данным международного регистра «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2». Архивъ внутренней медицины. 2023;13(2):116-28 [Batyushin MM, Trubnikova MA, Tarlovskaya EI, et al. Influence of kidney damage on the course and prognosis of COVID-19 infection according to the international registry “Analysis of the dynamics of comorbid diseases in patients who have undergone SARS-CoV-2 infection”. Archive of Internal Medicine. 2023;13(2):116-28 (in Russian)]. DOI:10.20514/2226-6704-2023-13-2-116-128
26. Шилов Е.М., Шилова М.М., Румянцева Е.И., и др. Эпидемиология COVID-19 у больных, находящихся на заместительной почечной терапии, в Российской Федерации в 2021 году (краткий отчет). Клиническая нефрология. 2022;2:6-8 [Shilov EM, Shilova MM, Rumyantseva EI, et al. Epidemiology of COVID-19 in Patients on Renal Replacement Therapy in the Russian Federation in 2021 (Summary). Clinical Nephrology. 2022;2:6-8 (in Russian)]. DOI:10.18565/nephrology.2022.2.6-8
27. Шутов Е.В., Большаков С.А., Котлярова Г.В., и др. Оценка гуморального ответа на вакцинацию Гам-Ковид-Вак (Sputnik V) против COVID-19 пациентов на амбулаторном диализе и перитонеальном диализе. Клиническая нефрология. 2022;3:8 [Shutov EV, Bol'shakov SA, Kotlyarova GV, et al. Evaluation of the humoral response to vaccination with Gam-Covid-Vak (Sputnik V) against COVID-19 in patients on ambulatory dialysis and peritoneal dialysis. Clinical Nephrology. 2022;3:8 (in Russian)].
DOI:10.18565/nephrology.2022.3.8-14
28. Ким И.Г., Новикова Л.И., Фролова Н.Ф., и др. Особенности вакцинопрофилактики COVID-19 у реципиентов почечного трансплантата. Нефрология и диализ. 2022;24(4):884-91 [Kim IG, Novikova LI, Frolova NF, et al. Features of COVID-19 vaccine prevention in kidney transplant recipients. Nephrology and Dialysis. 2022;24(4):884-91 (in Russian)]. DOI:10.28996/2618-9801-2022-4-884-891
29. Фролова Н.Ф., Ким И.Г., Ушакова А.И., и др. COVID-19 у больных, получающих лечение программным гемодиализом. Инфекционные болезни: новости, мнения, обучение. 2021;10(1):14-23 [Frolova NF, Kim IG, Ushakova AI, et al. COVID-19 in patients receiving treatment with program hemodialysis. Infectious Diseases: News, Opinions, Training. 2021;10(1):14‑23 (in Russian)]. DOI:10.33029/2305-3496-2021-10-1-14-23
30. Зубкин М.Л., Ким И.Г., Фролова Н.Ф., и др. Новая коронавирусная инфекция и гемодиализ: течение и предикторы неблагоприятного исхода. Нефрология и диализ. 2021;23(4):489-98 [Zubkin ML, Kim IG, Frolova NF, et al. Novel coronavirus infection and hemodialysis: course and predictors of adverse outcome. Nephrology and Dialysis. 2021;23(4):489-98 (in Russian)]. DOI:10.28996/2618-9801-2021-4-489-498
31. Ким И.Г., Артюхина Л.Ю., Фролова Н.Ф., и др. SARS-CoV-2 инфекция у реципиентов почечного трансплантата. Нефрология и диализ. 2021;23(2):174-84 [Kim IG, Artyukhina LYu, Frolova NF, et al. SARS-CoV-2 infection in kidney transplant recipients. Nephrology and Dialysis. 2021;23(2):174-84 (in Russian)]. DOI:10.28996/2618-9801-2021-2-174-184
32. Kim I, Frolova N, Artyukhina L, et al. MO934 COVID-19 in renal transplant recipients (RTR). Nephrol Dial Transplant. 2021;36(Suppl. 1):gfab110.0013. DOI:10.1093/ndt/gfab110.0013
33. Зубкин М.Л., Фролова Н.Ф., Ким И.Г., и др. COVID-19 у больных, получающих лечение программным гемодиализом: анализ результатов первого года пандемии. Терапевтический архив. 2021;93(11):1325-33 [Zubkin ML, Frolova NF, Kim IG, et al. COVID-19 in haemodialysis patients: result analysis of the first year of the pandemic. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(11):1325-33 (in Russian)]. DOI:10.26442/00403660.2021.11.201215
34. Aleshina OA, Zakurdaeva K, Vasileva AN, et al. Clinical Outcomes in Patients With COVID-19 and Hematologic Disease. Clin Lymphoma Myeloma Leuk. 2023;23(8):589-98. DOI:10.1016/j.clml.2023.04.002
35. Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. DOI:10.1186/s13045-021-01177-0
36. Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022;140(3):236-52. DOI:10.1182/blood.2021012251
37. Pagano L, Salmanton-García J, Marchesi F, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood. 2022;140(26):2773-87. DOI:10.1182/blood.2022017257
38. Sahota A, Tien A, Yao J, et al. Incidence, risk factors, and outcomes of COVID-19 infection in a large cohort of solid organ transplant recipients. Transplantation. 2022;106(12):2426. DOI:10.1097/TP.0000000000004371
39. Готье С.В., Шевченко А.О., Цирульникова О.М., и др. Особенности клинического течения коронавирусной инфекции COVID-19 у реципиентов сердца, почки, печени: первые результаты национального многоцентрового наблюдательного исследования «РОККОР-реципиент». Вестник трансплантологии и искусственных органов. 2020;22(3):8-17 [Gautier SV, Shevchenko AO, Tsirulnikova OM. Features of the clinical course of coronavirus infection COVID-19 in recipients of the heart, kidney, liver: the first results of the national multicenter observational study “ROCCOR-recipient”. Bulletin of Transplantology and Artificial Organs. 2020;22(3):8-17 (in Russian)]. DOI:10.15825/1995-1191-2020-3-8-17
40. Ma BM, Tam AR, Chan KW, et al. Immunogenicity and safety of COVID-19 vaccines in patients receiving renal replacement therapy: a systematic review and meta-analysis. Front Med (Lausanne). 2022;9:827859. DOI:10.3389/fmed.2022.827859
41. Sanders JF, Bemelman FJ, Messchendorp AL, et al. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2022;106(4):821. DOI:10.1097/TP.0000000000003983
42. Роппельт А.А., Лебедкина М.С., Чернов А.А., и др. Доконтактная профилактика новой коронавирусной инфекции COVID-19 препаратом тиксагевимаб/цилгавимаб у взрослых московских пациентов с первичными иммунодефицитами. Терапевтический архив. 2023;95(1):78-84 [Roppelt AA, Lebedkina MS, Chernov AA, et al. Pre-exposure prophylaxis of novel coronavirus infection COVID-19 with thixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(1):78‑84 (in Russian)]. DOI:10.26442/00403660.2023.01.202088
43. Milota T, Sobotková M, Smetanova J, et al. Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity – Results From a Multicenter Nationwide Study. Front Immunol. 2022;13:835770. DOI:10.3389/fimmu.2022.835770
44. Durkee-Shock JR, Keller MD. Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity. Ann Allergy Asthma Immunol. 2022;129(5):562-71.e1. DOI:10.1016/j.anai.2022.06.009
45. О внесении изменений в приказ Министерства здравоохранения Российской Федерации от 6 декабря 2021 г. №1122н. Режим доступа: https://regulation.gov.ru/Regulation/Npa/PublicView?npaID=140206. Ссылка активна на 22.08.2023 [On Amendments to the Order of the Ministry of Health of the Russian Federation from December 6, 2021 №1122n. Available at: https://regulation.gov.ru/Regulation/Npa/PublicView?npaID=140206. Accessed: 22.08.2023 (in Russian)].
46. ВМР – Временные методические рекомендации по профилактике, диагностике и лечению новой коронавирусной инфекции (COVID-19), версия 17. Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/252/original/%D0%92%D0%9C%D0%A0.... Ссылка активна на 12.07.2023 [Interim guidelines for the prevention, diagnosis and treatment of a new coronavirus infection (COVID-19), version 17. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/252/original/%D0%92%D0%9C%D0%A0.... Accessed: 12.07.2023 (in Russian)].
47. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab – cilgavimab) for prevention of COVID-19. New Engl J Med. 2022;386(23):2188-200. DOI:10.1056/NEJMoa2116620
48. Suribhatla R, Starkey T, Ionescu MC, et al. Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients. medRxiv. 2022:2022-11. DOI:10.1111/bjh.18782
49. Кокина М.Ю., Фомина Д.С., Лебедкина М.C., и др. Эффективность и безопасность применения двухкомпонентного препарата моноклональных антител к SARS-CoV-2 (тиксагевимаб + цилгавимаб) для доконтактной профилактики новой коронавирусной инфекции у иммунокомпрометированных пациентов детского возраста с ревматическими заболеваниями. Предварительные результаты первого в Российской Федерации проспективного наблюдательного когортного исследования. Вопросы практической педиатрии. 2023;18(1):16-26 [Kokina MYu, Fomina DS, Lebedkina MS. Efficacy and safety of using a two-component preparation of monoclonal antibodies to SARS-CoV-2 (tixagevimab + cilgavimab) for pre-exposure prophylaxis of a new coronavirus infection in immunocompromised pediatric patients with rheumatic diseases. Preliminary results of the first prospective observational cohort study in the Russian Federation. Questions of Practical Pediatrics. 2023;18(1):16-26 (in Russian)]. DOI:10.20953/1817-7646-2023-1-16-26
50. Валиахметова Ч.Х., Сираева Э.И. Современные возможности улучшения результатов профилактики и течения инфекции COVID-19 у пациентов с лимфопролиферативными заболеваниями (региональный анализ). Онкогематология. 2023;18(2):68‑73 [Valiakhmetova ChKh, Siraeva EI. Modern opportunities to improve the results of prevention and course of COVID-19 infection in patients with lymphoproliferative diseases (regional analysis). Oncohematology. 2023;18(2):68-73 (in Russian)]. DOI:10.17650/1818-8346-2023-18-2-68-73
51. Бекетова Т.В., Левина Н.О., Дубинская М.В., и др. Опыт применения тиксагевимаба и цилгавимаба (Эвушелд) у 86 ревматологических пациентов, получающих анти-В-клеточную терапию ритуксимабом. Научно-практическая ревматология. 2023;61(2):158-64 [Beketova TV, Levina NO, Dubinskaya MV. Experience with thixagevimab and cilgavimab (Evusheld) in 86 rheumatic patients receiving anti-B-cell therapy with rituximab. Scientific and Practical Rheumatology. 2023;61(2):158-64 (in Russian)].
DOI:10.47360/1995-4484-2023-158-164
52. Валиахметова Ч.Х., Сираева Э.Р., Измайлов А.А. Эффективная профилактика инфекции COVID-19 у онкологических пациентов, получающих противоопухолевую лекарственную терапию (региональный анализ). Современная онкология. 2023;25(1):111-14 [Valiakhmetova ChKh, Siraeva ER, Izmailov AA. Effective prevention of COVID-19 infection in cancer patients receiving antitumor drug therapy (regional analysis). Modern Oncology. 2023;25(1):111-14 (in Russian)]. DOI:10.26442/18151434.2023.1.202170
53. Антонов В.Н., Игнатова Г.Л. Эффективность и безопасность иммунизации пациентов с хронической обструктивной болезнью легких моноклональными антителами. Терапевтический архив. 2023;95(3):243-47 [Antonov VN, Ignatova GL. Efficacy and safety of immunization of patients with chronic obstructive pulmonary disease with monoclonal antibodies. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(3):243-7 (in Russian)]. DOI:10.26442/00403660.2023.03.202146
54. Балабохина М.В., Назарова О.И., Скотникова Е.А., и др. Опыт применения препарата тиксагевимаб/цилгавимаб с целью доконтактной профилактики COVID-19 у больных ВИЧ-инфекцией на территории Омской области. Лечащий врач. 2023;3(26):48-51 [Balabokhina MV, Nazarova OI, Skotnikova EA, et al. Experience with the use of thixagevimab/cilgavimab for pre-exposure prophylaxis of COVID-19 in patients with HIV infection in the Omsk region. Lechaschi Vrach. 2023;3(26):48-51 (in Russian)]. DOI:10.51793/OS.2023.26.3.008
55. Aleshina (Gavrilina) O, Zhabrailova A, Troistskaya V. P1574: Efficacy and safety of tixagevimab and cilgavimab (Evusheld) in patients with hematological malignancies. Hemasphere. 2023;7(Suppl.):e68761f9. DOI:10.1097/01.HS9.0000973172.68761.f9
56. Постановление Правительства РФ от 3 апреля 2020 г. №441 «Об особенностях обращения лекарственных препаратов для медицинского применения, которые предназначены для применения в условиях угрозы возникновения, возникновения и ликвидации чрезвычайной ситуации и для организации оказания медицинской помощи лицам, пострадавшим в результате чрезвычайных ситуаций, предупреждения чрезвычайных ситуаций, профилактики и лечения заболеваний, представляющих опасность для окружающих, заболеваний и поражений, полученных в результате воздействия неблагоприятных химических, биологических, радиационных факторов». Режим доступа http://government.ru/docs/39399/ Ссылка активна на 12.07.2023 [Decree of the Government of the Russian Federation of April 3, 2020 №441 “On the peculiarities of the circulation of medicinal products for medical use, which are intended for use in conditions of the threat of the emergence, occurrence and liquidation of an emergency and for organizing the provision of medical care to persons affected by emergencies, prevention emergency situations, prevention and treatment of diseases that pose a danger to others, diseases and injuries resulting from exposure to adverse chemical, biological, radiation factors”. Available at: http://government.ru/docs/39399/ Accessed: 12.07.2023 (in Russian)].
57. Постановление Правительства РФ от 28 августа 2014 г. №871 «Об утверждении Правил формирования перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи». Режим доступа: http://government.ru/docs/all/131319/ Ссылка активна на 12.07.2023 [Decree of the Government of the Russian Federation of August 28, 2014 №871 “On approval of the Rules for the formation of lists of drugs for medical use and the minimum range of drugs necessary for the provision of medical care”. Available at: http://government.ru/docs/all/131319/ Accessed: 12.07.2023 (in Russian)].
2. Stopcoronavirus.rf – official Internet resource for informing the population about coronavirus (COVID-19). Available at: https://стопкоронавирус.рф/ Accessed: 12.07.2023 (in Russian).
3. Information for Persons Who Are Immunocompromised Regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages. Available at: https://www.cdc.gov/mmwr/volumes/72/wr/mm7205e3.htm. Accessed: 12.07.2023.
4. Nussenblatt V, Roder AE, Das S, et al. Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion. medRxiv [Preprint]. 2021:2021.10.02.21264267. DOI:10.1101/2021.10.02.21264267
5. Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592(7853):277-82. DOI:10.1038/s41586-021-03291-y
6. Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New Engl J Med. 2021;385(13):1244-6. DOI:10.1056/NEJMc2111462
7. Cheung MW, Dayam RM, Shapiro JR, et al. Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in immunocompromised adult patients. J Immunol. 2023;211(3):351-64. DOI:10.4049/jimmunol.2300190
8. Turtle L, Thorpe M, Drake TM, et al. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the who ISARIC CCP-UK prospective cohort study. PLoS Med. 2023;20(1):e1004086. DOI:10.1371/journal.pmed.1004086
9. Singson JRC, Kirley PD, Pham H, et al. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19 – COVID-NET, 10 states, March 2020 – February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(27):878. DOI:10.15585/mmwr.mm7127a3
10. Brosh-Nissimov T, Hussein K, Wiener-Well Y, et al. Hospitalized patients with severe coronavirus disease 2019 during the omicron wave in Israel: Benefits of a fourth vaccine dose. Clin Infect Dis. 2023;76(3):e234-9. DOI:10.1093/cid/ciac501
11. All-Russian Union of Patients. Analysis of the impact of coronavirus infection on immunocompromised people. Available at: https://vspru.ru/news/2023/04/10042023-gruppa-riska-silno-riskuet. Accessed: 09.06.2023 (in Russian).
12. Nasonov EL, Lila AM, Mazurov VI, et al. Coronavirus disease 2019 (COVID-19) and immunoinflammatory rheumatic diseases. Recommendations of the All-Russian public organization “Association of Rheumatologists of Russia”. Scientific and Practical Rheumatology. 2021;59(3):239-54 (in Russian). DOI:10.47360/1995-4484-2021-239-254
13. Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(10):1255-65. DOI:10.1136/annrheumdis-2021-221244
14. Saleem B, Ross RL, Bissell LA, et al. Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses. RMD Open. 2022;8(1):e002050. DOI:10.1136/rmdopen-2021-002050
15. Khemiri H, Ayouni K, Triki H, et al. SARS-CoV-2 infection in pediatric population before and during the Delta (B. 1.617. 2) and Omicron (B. 1.1. 529) variants era. Virol J.
2022;19(1):1-16. DOI:10.1186/s12985-022-01873-4
16. Leidman E, Duca LM, Omura JD, et al. COVID-19 trends among persons aged 0–24 years – United States, March 1 – December 12, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(3):88. DOI:10.15585/mmwr.mm7003e1
17. Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr. 2021;180(7):2019-34. DOI:10.1007/s00431-021-03993-5
18. Brough HA, Kalayci O, Sediva A, et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – the 2020 COVID-19 pandemic: a statement from the EAACI-section on pediatrics. Pediatr Allergy Immunol. 2020;31(5):442-8. DOI:10.1111/pai.13262
19. Jansen MHA, Rondaan C, Legger GE, et al. EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Ann Rheum Dis. 2023;82(1):35-47. DOI:10.1136/annrheumdis-2022-222574
20. Kato M. New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors. Immunol Med. 2020;43(2):72-8. DOI:10.1080/25785826.2020.1751908
21. Kriulin IA, Alekseeva EI, Dvoryakovskaya TM, et al. Hemophagocytic syndrome: mechanisms of development, clinical manifestations, therapeutic technologies. Clinical Practice in Pediatrics. 2021;16(6):94-102 (in Russian). DOI:10.20953/1817-7646-2021-6-94-102
22. Shilov EM, Esayan AM, Shilova MM, et al. Possible structure of stages of chronic kidney disease in the Russian Federation. Clinical Nephrology. 2021;4:6-7 (in Russian). DOI:10.18565/nephrology.2021.4.6-7
23. Shilov EM, Shilova MM, Rumyantseva EI, et al. The state of the nephrological service in the Russian Federation: renal replacement therapy in the period from 2017 to 2021. Clinical Nephrology. 2021;1:6‑15 (in Russian). DOI:10.18565/nephrology.2022.1.6-15
24. Kotenko ON, Vasina NV, Marchenkova LV, et al. State of replacement therapy for chronic renal failure in Moscow in 2015–2020. Clinical Nephrology. 2021;1:13-9 (in Russian). DOI:10.18565/nephrology.2021.1.13-19
25. Batyushin MM, Trubnikova MA, Tarlovskaya EI, et al. Influence of kidney damage on the course and prognosis of COVID-19 infection according to the international registry “Analysis of the dynamics of comorbid diseases in patients who have undergone SARS-CoV-2 infection”. Archive of Internal Medicine. 2023;13(2):116-28 (in Russian).
DOI:10.20514/2226-6704-2023-13-2-116-128
26. Shilov EM, Shilova MM, Rumyantseva EI, et al. Epidemiology of COVID-19 in Patients on Renal Replacement Therapy in the Russian Federation in 2021 (Summary). Clinical Nephrology. 2022;2:6-8 (in Russian). DOI:10.18565/nephrology.2022.2.6-8
27. Shutov EV, Bol'shakov SA, Kotlyarova GV, et al. Evaluation of the humoral response to vaccination with Gam-Covid-Vak (Sputnik V) against COVID-19 in patients on ambulatory dialysis and peritoneal dialysis. Clinical Nephrology. 2022;3:8 (in Russian). DOI:10.18565/nephrology.2022.3.8-14
28. Kim IG, Novikova LI, Frolova NF, et al. Features of COVID-19 vaccine prevention in kidney transplant recipients. Nephrology and Dialysis. 2022;24(4):884-91 (in Russian). DOI:10.28996/2618-9801-2022-4-884-891
29. Frolova NF, Kim IG, Ushakova AI, et al. COVID-19 in patients receiving treatment with program hemodialysis. Infectious Diseases: News, Opinions, Training. 2021;10(1):14‑23 (in Russian). DOI:10.33029/2305-3496-2021-10-1-14-23
30. Zubkin ML, Kim IG, Frolova NF, et al. Novel coronavirus infection and hemodialysis: course and predictors of adverse outcome. Nephrology and Dialysis. 2021;23(4):489-98 (in Russian). DOI:10.28996/2618-9801-2021-4-489-498
31. Kim IG, Artyukhina LYu, Frolova NF, et al. SARS-CoV-2 infection in kidney transplant recipients. Nephrology and Dialysis. 2021;23(2):174-84 (in Russian).
DOI:10.28996/2618-9801-2021-2-174-184
32. Kim I, Frolova N, Artyukhina L, et al. MO934 COVID-19 in renal transplant recipients (RTR). Nephrol Dial Transplant. 2021;36(Suppl. 1):gfab110.0013.
DOI:10.1093/ndt/gfab110.0013
33. Zubkin ML, Frolova NF, Kim IG, et al. COVID-19 in haemodialysis patients: result analysis of the first year of the pandemic. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(11):1325-33 (in Russian). DOI:10.26442/00403660.2021.11.201215
34. Aleshina OA, Zakurdaeva K, Vasileva AN, et al. Clinical Outcomes in Patients With COVID-19 and Hematologic Disease. Clin Lymphoma Myeloma Leuk. 2023;23(8):589-98. DOI:10.1016/j.clml.2023.04.002
35. Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. DOI:10.1186/s13045-021-01177-0
36. Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022;140(3):236-52. DOI:10.1182/blood.2021012251
37. Pagano L, Salmanton-García J, Marchesi F, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood. 2022;140(26):2773-87. DOI:10.1182/blood.2022017257
38. Sahota A, Tien A, Yao J, et al. Incidence, risk factors, and outcomes of COVID-19 infection in a large cohort of solid organ transplant recipients. Transplantation. 2022;106(12):2426. DOI:10.1097/TP.0000000000004371
39. Gautier SV, Shevchenko AO, Tsirulnikova OM. Features of the clinical course of coronavirus infection COVID-19 in recipients of the heart, kidney, liver: the first results of the national multicenter observational study “ROCCOR-recipient”. Bulletin of Transplantology and Artificial Organs. 2020;22(3):8-17 (in Russian). DOI:10.15825/1995-1191-2020-3-8-17
40. Ma BM, Tam AR, Chan KW, et al. Immunogenicity and safety of COVID-19 vaccines in patients receiving renal replacement therapy: a systematic review and meta-analysis. Front Med (Lausanne). 2022;9:827859. DOI:10.3389/fmed.2022.827859
41. Sanders JF, Bemelman FJ, Messchendorp AL, et al. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2022;106(4):821. DOI:10.1097/TP.0000000000003983
42. Roppelt AA, Lebedkina MS, Chernov AA, et al. Pre-exposure prophylaxis of novel coronavirus infection COVID-19 with thixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(1):78‑84 (in Russian). DOI:10.26442/00403660.2023.01.202088
43. Milota T, Sobotková M, Smetanova J, et al. Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity – Results From a Multicenter Nationwide Study. Front Immunol. 2022;13:835770. DOI:10.3389/fimmu.2022.835770
44. Durkee-Shock JR, Keller MD. Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity. Ann Allergy Asthma Immunol. 2022;129(5):562-71.e1. DOI:10.1016/j.anai.2022.06.009
45. On Amendments to the Order of the Ministry of Health of the Russian Federation from December 6, 2021 №1122n. Available at: https://regulation.gov.ru/Regulation/Npa/PublicView?npaID=140206. Accessed: 22.08.2023 (in Russian).
46. Interim guidelines for the prevention, diagnosis and treatment of a new coronavirus infection (COVID-19), version 17. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/252/original/%D0%92%D0%9C%D0%A0.... Accessed: 12.07.2023 (in Russian).
47. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab – cilgavimab) for prevention of COVID-19. New Engl J Med. 2022;386(23):2188-200. DOI:10.1056/NEJMoa2116620
48. Suribhatla R, Starkey T, Ionescu MC, et al. Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients. medRxiv. 2022:2022-11. DOI:10.1111/bjh.18782
49. Kokina MYu, Fomina DS, Lebedkina MS. Efficacy and safety of using a two-component preparation of monoclonal antibodies to SARS-CoV-2 (tixagevimab + cilgavimab) for pre-exposure prophylaxis of a new coronavirus infection in immunocompromised pediatric patients with rheumatic diseases. Preliminary results of the first prospective observational cohort study in the Russian Federation. Questions of Practical Pediatrics. 2023;18(1):16-26 (in Russian). DOI:10.20953/1817-7646-2023-1-16-26
50. Valiakhmetova ChKh, Siraeva EI. Modern opportunities to improve the results of prevention and course of COVID-19 infection in patients with lymphoproliferative diseases (regional analysis). Oncohematology. 2023;18(2):68-73 (in Russian). DOI:10.17650/1818-8346-2023-18-2-68-73
51. Beketova TV, Levina NO, Dubinskaya MV. Experience with thixagevimab and cilgavimab (Evusheld) in 86 rheumatic patients receiving anti-B-cell therapy with rituximab. Scientific and Practical Rheumatology. 2023;61(2):158-64 (in Russian). DOI:10.47360/1995-4484-2023-158-164
52. Valiakhmetova ChKh, Siraeva ER, Izmailov AA. Effective prevention of COVID-19 infection in cancer patients receiving antitumor drug therapy (regional analysis). Modern Oncology. 2023;25(1):111-14 (in Russian). DOI:10.26442/18151434.2023.1.202170
53. Antonov VN, Ignatova GL. Efficacy and safety of immunization of patients with chronic obstructive pulmonary disease with monoclonal antibodies. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(3):243-7 (in Russian). DOI:10.26442/00403660.2023.03.202146
54. Balabokhina MV, Nazarova OI, Skotnikova EA, et al. Experience with the use of thixagevimab/cilgavimab for pre-exposure prophylaxis of COVID-19 in patients with HIV infection in the Omsk region. Lechaschi Vrach. 2023;3(26):48-51 (in Russian). DOI:10.51793/OS.2023.26.3.008
55. Aleshina (Gavrilina) O, Zhabrailova A, Troistskaya V. P1574: Efficacy and safety of tixagevimab and cilgavimab (Evusheld) in patients with hematological malignancies. Hemasphere. 2023;7(Suppl.):e68761f9. DOI:10.1097/01.HS9.0000973172.68761.f9
56. Decree of the Government of the Russian Federation of April 3, 2020 №441 “On the peculiarities of the circulation of medicinal products for medical use, which are intended for use in conditions of the threat of the emergence, occurrence and liquidation of an emergency and for organizing the provision of medical care to persons affected by emergencies, prevention emergency situations, prevention and treatment of diseases that pose a danger to others, diseases and injuries resulting from exposure to adverse chemical, biological, radiation factors”. Available at: http://government.ru/docs/39399/ Accessed: 12.07.2023 (in Russian).
57. Decree of the Government of the Russian Federation of August 28, 2014 №871 “On approval of the Rules for the formation of lists of drugs for medical use and the minimum range of drugs necessary for the provision of medical care”. Available at: http://government.ru/docs/all/131319/ Accessed: 12.07.2023 (in Russian).
2. Стопкоронавирус.рф – официальный интернет-ресурс для информирования населения по вопросам коронавируса (COVID-19). Режим доступа: https://стопкоронавирус.рф/ Ссылка активна на 12.07.2023 [Stopcoronavirus.rf – official Internet resource for informing the population about coronavirus (COVID-19). Available at: https://стопкоронавирус.рф/ Accessed: 12.07.2023 (in Russian)].
3. Information for Persons Who Are Immunocompromised Regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages. Available at: https://www.cdc.gov/mmwr/volumes/72/wr/mm7205e3.htm. Accessed: 12.07.2023.
4. Nussenblatt V, Roder AE, Das S, et al. Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion. medRxiv [Preprint]. 2021:2021.10.02.21264267. DOI:10.1101/2021.10.02.21264267
5. Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592(7853):277-82. DOI:10.1038/s41586-021-03291-y
6. Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New Engl J Med. 2021;385(13):1244-6. DOI:10.1056/NEJMc2111462
7. Cheung MW, Dayam RM, Shapiro JR, et al. Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in immunocompromised adult patients. J Immunol. 2023;211(3):351-64. DOI:10.4049/jimmunol.2300190
8. Turtle L, Thorpe M, Drake TM, et al. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the who ISARIC CCP-UK prospective cohort study. PLoS Med. 2023;20(1):e1004086. DOI:10.1371/journal.pmed.1004086
9. Singson JRC, Kirley PD, Pham H, et al. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19 – COVID-NET, 10 states, March 2020 – February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(27):878. DOI:10.15585/mmwr.mm7127a3
10. Brosh-Nissimov T, Hussein K, Wiener-Well Y, et al. Hospitalized patients with severe coronavirus disease 2019 during the omicron wave in Israel: Benefits of a fourth vaccine dose. Clin Infect Dis. 2023;76(3):e234-9. DOI:10.1093/cid/ciac501
11. Всероссийский союз пациентов. Анализ влияния коронавирусной инфекции на людей с ослабленным иммунитетом. Режим доступа: https://vspru.ru/news/2023/04/10042023-gruppa-riska-silno-riskuet. Ссылка активна на 09.06.2023 [All-Russian Union of Patients. Analysis of the impact of coronavirus infection on immunocompromised people. Available at: https://vspru.ru/news/2023/04/10042023-gruppa-riska-silno-riskuet. Accessed: 09.06.2023 (in Russian)].
12. Насонов Е.Л., Лила А.М., Мазуров В.И., и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021;59(3):239-54 [Nasonov EL, Lila AM, Mazurov VI, et al. Coronavirus disease 2019 (COVID-19) and immunoinflammatory rheumatic diseases. Recommendations of the All-Russian public organization “Association of Rheumatologists of Russia”. Scientific and Practical Rheumatology. 2021;59(3):239-54 (in Russian)]. DOI:10.47360/1995-4484-2021-239-254
13. Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(10):1255-65. DOI:10.1136/annrheumdis-2021-221244
14. Saleem B, Ross RL, Bissell LA, et al. Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses. RMD Open. 2022;8(1):e002050. DOI:10.1136/rmdopen-2021-002050
15. Khemiri H, Ayouni K, Triki H, et al. SARS-CoV-2 infection in pediatric population before and during the Delta (B. 1.617. 2) and Omicron (B. 1.1. 529) variants era. Virol J.
2022;19(1):1-16. DOI:10.1186/s12985-022-01873-4
16. Leidman E, Duca LM, Omura JD, et al. COVID-19 trends among persons aged 0–24 years – United States, March 1 – December 12, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(3):88. DOI:10.15585/mmwr.mm7003e1
17. Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr. 2021;180(7):2019-34. DOI:10.1007/s00431-021-03993-5
18. Brough HA, Kalayci O, Sediva A, et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – the 2020 COVID-19 pandemic: a statement from the EAACI-section on pediatrics. Pediatr Allergy Immunol. 2020;31(5):442-8. DOI:10.1111/pai.13262
19. Jansen MHA, Rondaan C, Legger GE, et al. EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Ann Rheum Dis. 2023;82(1):35-47. DOI:10.1136/annrheumdis-2022-222574
20. Kato M. New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors. Immunol Med. 2020;43(2):72-8. DOI:10.1080/25785826.2020.1751908
21. Криулин И.А., Алексеева Е.И., Дворяковская Т.М., и др. Гемофагоцитарный синдром: механизмы развития, клинические проявления, терапевтические технологии. Вопросы практической педиатрии. 2021;16(6):94-102 [Kriulin IA, Alekseeva EI, Dvoryakovskaya TM, et al. Hemophagocytic syndrome: mechanisms of development, clinical manifestations, therapeutic technologies. Clinical Practice in Pediatrics. 2021;16(6):94-102 (in Russian)]. DOI:10.20953/1817-7646-2021-6-94-102
22. Шилов Е.М., Есаян А.М., Шилова М.М., и др. Возможная структура стадий хронической болезни почек в Российской Федерации. Клиническая нефрология. 2021;4:6-7 [Shilov EM, Esayan AM, Shilova MM, et al. Possible structure of stages of chronic kidney disease in the Russian Federation. Clinical Nephrology. 2021;4:6-7 (in Russian)]. DOI:10.18565/nephrology.2021.4.6-7
23. Шилов Е.М., Шилова М.М., Румянцева Е.И., и др. Состояние нефрологической службы в Российской Федерации: заместительная почечная терапия в период с 2017 по 2021 г. Клиническая нефрология. 2021;1:6-15 [Shilov EM, Shilova MM, Rumyantseva EI, et al. The state of the nephrological service in the Russian Federation: renal replacement therapy in the period from 2017 to 2021. Clinical Nephrology. 2021;1:6‑15 (in Russian)]. DOI:10.18565/nephrology.2022.1.6-15
24. Котенко О.Н., Васина Н.В., Марченкова Л.В., и др. Состояние заместительной терапии хронической почечной недостаточности в Москве в 2015–2020 гг. Клиническая нефрология. 2021;1:13-9 [Kotenko ON, Vasina NV, Marchenkova LV, et al. State of replacement therapy for chronic renal failure in Moscow in 2015–2020. Clinical Nephrology.
2021;1:13-9 (in Russian)]. DOI:10.18565/nephrology.2021.1.13-19
25. Батюшин М.М., Трубникова М.А., Тарловская Е.И., и др. Влияние поражения почек на течение и прогноз при инфекции COVID-19 по данным международного регистра «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2». Архивъ внутренней медицины. 2023;13(2):116-28 [Batyushin MM, Trubnikova MA, Tarlovskaya EI, et al. Influence of kidney damage on the course and prognosis of COVID-19 infection according to the international registry “Analysis of the dynamics of comorbid diseases in patients who have undergone SARS-CoV-2 infection”. Archive of Internal Medicine. 2023;13(2):116-28 (in Russian)]. DOI:10.20514/2226-6704-2023-13-2-116-128
26. Шилов Е.М., Шилова М.М., Румянцева Е.И., и др. Эпидемиология COVID-19 у больных, находящихся на заместительной почечной терапии, в Российской Федерации в 2021 году (краткий отчет). Клиническая нефрология. 2022;2:6-8 [Shilov EM, Shilova MM, Rumyantseva EI, et al. Epidemiology of COVID-19 in Patients on Renal Replacement Therapy in the Russian Federation in 2021 (Summary). Clinical Nephrology. 2022;2:6-8 (in Russian)]. DOI:10.18565/nephrology.2022.2.6-8
27. Шутов Е.В., Большаков С.А., Котлярова Г.В., и др. Оценка гуморального ответа на вакцинацию Гам-Ковид-Вак (Sputnik V) против COVID-19 пациентов на амбулаторном диализе и перитонеальном диализе. Клиническая нефрология. 2022;3:8 [Shutov EV, Bol'shakov SA, Kotlyarova GV, et al. Evaluation of the humoral response to vaccination with Gam-Covid-Vak (Sputnik V) against COVID-19 in patients on ambulatory dialysis and peritoneal dialysis. Clinical Nephrology. 2022;3:8 (in Russian)].
DOI:10.18565/nephrology.2022.3.8-14
28. Ким И.Г., Новикова Л.И., Фролова Н.Ф., и др. Особенности вакцинопрофилактики COVID-19 у реципиентов почечного трансплантата. Нефрология и диализ. 2022;24(4):884-91 [Kim IG, Novikova LI, Frolova NF, et al. Features of COVID-19 vaccine prevention in kidney transplant recipients. Nephrology and Dialysis. 2022;24(4):884-91 (in Russian)]. DOI:10.28996/2618-9801-2022-4-884-891
29. Фролова Н.Ф., Ким И.Г., Ушакова А.И., и др. COVID-19 у больных, получающих лечение программным гемодиализом. Инфекционные болезни: новости, мнения, обучение. 2021;10(1):14-23 [Frolova NF, Kim IG, Ushakova AI, et al. COVID-19 in patients receiving treatment with program hemodialysis. Infectious Diseases: News, Opinions, Training. 2021;10(1):14‑23 (in Russian)]. DOI:10.33029/2305-3496-2021-10-1-14-23
30. Зубкин М.Л., Ким И.Г., Фролова Н.Ф., и др. Новая коронавирусная инфекция и гемодиализ: течение и предикторы неблагоприятного исхода. Нефрология и диализ. 2021;23(4):489-98 [Zubkin ML, Kim IG, Frolova NF, et al. Novel coronavirus infection and hemodialysis: course and predictors of adverse outcome. Nephrology and Dialysis. 2021;23(4):489-98 (in Russian)]. DOI:10.28996/2618-9801-2021-4-489-498
31. Ким И.Г., Артюхина Л.Ю., Фролова Н.Ф., и др. SARS-CoV-2 инфекция у реципиентов почечного трансплантата. Нефрология и диализ. 2021;23(2):174-84 [Kim IG, Artyukhina LYu, Frolova NF, et al. SARS-CoV-2 infection in kidney transplant recipients. Nephrology and Dialysis. 2021;23(2):174-84 (in Russian)]. DOI:10.28996/2618-9801-2021-2-174-184
32. Kim I, Frolova N, Artyukhina L, et al. MO934 COVID-19 in renal transplant recipients (RTR). Nephrol Dial Transplant. 2021;36(Suppl. 1):gfab110.0013. DOI:10.1093/ndt/gfab110.0013
33. Зубкин М.Л., Фролова Н.Ф., Ким И.Г., и др. COVID-19 у больных, получающих лечение программным гемодиализом: анализ результатов первого года пандемии. Терапевтический архив. 2021;93(11):1325-33 [Zubkin ML, Frolova NF, Kim IG, et al. COVID-19 in haemodialysis patients: result analysis of the first year of the pandemic. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(11):1325-33 (in Russian)]. DOI:10.26442/00403660.2021.11.201215
34. Aleshina OA, Zakurdaeva K, Vasileva AN, et al. Clinical Outcomes in Patients With COVID-19 and Hematologic Disease. Clin Lymphoma Myeloma Leuk. 2023;23(8):589-98. DOI:10.1016/j.clml.2023.04.002
35. Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. DOI:10.1186/s13045-021-01177-0
36. Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022;140(3):236-52. DOI:10.1182/blood.2021012251
37. Pagano L, Salmanton-García J, Marchesi F, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood. 2022;140(26):2773-87. DOI:10.1182/blood.2022017257
38. Sahota A, Tien A, Yao J, et al. Incidence, risk factors, and outcomes of COVID-19 infection in a large cohort of solid organ transplant recipients. Transplantation. 2022;106(12):2426. DOI:10.1097/TP.0000000000004371
39. Готье С.В., Шевченко А.О., Цирульникова О.М., и др. Особенности клинического течения коронавирусной инфекции COVID-19 у реципиентов сердца, почки, печени: первые результаты национального многоцентрового наблюдательного исследования «РОККОР-реципиент». Вестник трансплантологии и искусственных органов. 2020;22(3):8-17 [Gautier SV, Shevchenko AO, Tsirulnikova OM. Features of the clinical course of coronavirus infection COVID-19 in recipients of the heart, kidney, liver: the first results of the national multicenter observational study “ROCCOR-recipient”. Bulletin of Transplantology and Artificial Organs. 2020;22(3):8-17 (in Russian)]. DOI:10.15825/1995-1191-2020-3-8-17
40. Ma BM, Tam AR, Chan KW, et al. Immunogenicity and safety of COVID-19 vaccines in patients receiving renal replacement therapy: a systematic review and meta-analysis. Front Med (Lausanne). 2022;9:827859. DOI:10.3389/fmed.2022.827859
41. Sanders JF, Bemelman FJ, Messchendorp AL, et al. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2022;106(4):821. DOI:10.1097/TP.0000000000003983
42. Роппельт А.А., Лебедкина М.С., Чернов А.А., и др. Доконтактная профилактика новой коронавирусной инфекции COVID-19 препаратом тиксагевимаб/цилгавимаб у взрослых московских пациентов с первичными иммунодефицитами. Терапевтический архив. 2023;95(1):78-84 [Roppelt AA, Lebedkina MS, Chernov AA, et al. Pre-exposure prophylaxis of novel coronavirus infection COVID-19 with thixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(1):78‑84 (in Russian)]. DOI:10.26442/00403660.2023.01.202088
43. Milota T, Sobotková M, Smetanova J, et al. Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity – Results From a Multicenter Nationwide Study. Front Immunol. 2022;13:835770. DOI:10.3389/fimmu.2022.835770
44. Durkee-Shock JR, Keller MD. Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity. Ann Allergy Asthma Immunol. 2022;129(5):562-71.e1. DOI:10.1016/j.anai.2022.06.009
45. О внесении изменений в приказ Министерства здравоохранения Российской Федерации от 6 декабря 2021 г. №1122н. Режим доступа: https://regulation.gov.ru/Regulation/Npa/PublicView?npaID=140206. Ссылка активна на 22.08.2023 [On Amendments to the Order of the Ministry of Health of the Russian Federation from December 6, 2021 №1122n. Available at: https://regulation.gov.ru/Regulation/Npa/PublicView?npaID=140206. Accessed: 22.08.2023 (in Russian)].
46. ВМР – Временные методические рекомендации по профилактике, диагностике и лечению новой коронавирусной инфекции (COVID-19), версия 17. Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/252/original/%D0%92%D0%9C%D0%A0.... Ссылка активна на 12.07.2023 [Interim guidelines for the prevention, diagnosis and treatment of a new coronavirus infection (COVID-19), version 17. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/252/original/%D0%92%D0%9C%D0%A0.... Accessed: 12.07.2023 (in Russian)].
47. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab – cilgavimab) for prevention of COVID-19. New Engl J Med. 2022;386(23):2188-200. DOI:10.1056/NEJMoa2116620
48. Suribhatla R, Starkey T, Ionescu MC, et al. Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients. medRxiv. 2022:2022-11. DOI:10.1111/bjh.18782
49. Кокина М.Ю., Фомина Д.С., Лебедкина М.C., и др. Эффективность и безопасность применения двухкомпонентного препарата моноклональных антител к SARS-CoV-2 (тиксагевимаб + цилгавимаб) для доконтактной профилактики новой коронавирусной инфекции у иммунокомпрометированных пациентов детского возраста с ревматическими заболеваниями. Предварительные результаты первого в Российской Федерации проспективного наблюдательного когортного исследования. Вопросы практической педиатрии. 2023;18(1):16-26 [Kokina MYu, Fomina DS, Lebedkina MS. Efficacy and safety of using a two-component preparation of monoclonal antibodies to SARS-CoV-2 (tixagevimab + cilgavimab) for pre-exposure prophylaxis of a new coronavirus infection in immunocompromised pediatric patients with rheumatic diseases. Preliminary results of the first prospective observational cohort study in the Russian Federation. Questions of Practical Pediatrics. 2023;18(1):16-26 (in Russian)]. DOI:10.20953/1817-7646-2023-1-16-26
50. Валиахметова Ч.Х., Сираева Э.И. Современные возможности улучшения результатов профилактики и течения инфекции COVID-19 у пациентов с лимфопролиферативными заболеваниями (региональный анализ). Онкогематология. 2023;18(2):68‑73 [Valiakhmetova ChKh, Siraeva EI. Modern opportunities to improve the results of prevention and course of COVID-19 infection in patients with lymphoproliferative diseases (regional analysis). Oncohematology. 2023;18(2):68-73 (in Russian)]. DOI:10.17650/1818-8346-2023-18-2-68-73
51. Бекетова Т.В., Левина Н.О., Дубинская М.В., и др. Опыт применения тиксагевимаба и цилгавимаба (Эвушелд) у 86 ревматологических пациентов, получающих анти-В-клеточную терапию ритуксимабом. Научно-практическая ревматология. 2023;61(2):158-64 [Beketova TV, Levina NO, Dubinskaya MV. Experience with thixagevimab and cilgavimab (Evusheld) in 86 rheumatic patients receiving anti-B-cell therapy with rituximab. Scientific and Practical Rheumatology. 2023;61(2):158-64 (in Russian)].
DOI:10.47360/1995-4484-2023-158-164
52. Валиахметова Ч.Х., Сираева Э.Р., Измайлов А.А. Эффективная профилактика инфекции COVID-19 у онкологических пациентов, получающих противоопухолевую лекарственную терапию (региональный анализ). Современная онкология. 2023;25(1):111-14 [Valiakhmetova ChKh, Siraeva ER, Izmailov AA. Effective prevention of COVID-19 infection in cancer patients receiving antitumor drug therapy (regional analysis). Modern Oncology. 2023;25(1):111-14 (in Russian)]. DOI:10.26442/18151434.2023.1.202170
53. Антонов В.Н., Игнатова Г.Л. Эффективность и безопасность иммунизации пациентов с хронической обструктивной болезнью легких моноклональными антителами. Терапевтический архив. 2023;95(3):243-47 [Antonov VN, Ignatova GL. Efficacy and safety of immunization of patients with chronic obstructive pulmonary disease with monoclonal antibodies. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(3):243-7 (in Russian)]. DOI:10.26442/00403660.2023.03.202146
54. Балабохина М.В., Назарова О.И., Скотникова Е.А., и др. Опыт применения препарата тиксагевимаб/цилгавимаб с целью доконтактной профилактики COVID-19 у больных ВИЧ-инфекцией на территории Омской области. Лечащий врач. 2023;3(26):48-51 [Balabokhina MV, Nazarova OI, Skotnikova EA, et al. Experience with the use of thixagevimab/cilgavimab for pre-exposure prophylaxis of COVID-19 in patients with HIV infection in the Omsk region. Lechaschi Vrach. 2023;3(26):48-51 (in Russian)]. DOI:10.51793/OS.2023.26.3.008
55. Aleshina (Gavrilina) O, Zhabrailova A, Troistskaya V. P1574: Efficacy and safety of tixagevimab and cilgavimab (Evusheld) in patients with hematological malignancies. Hemasphere. 2023;7(Suppl.):e68761f9. DOI:10.1097/01.HS9.0000973172.68761.f9
56. Постановление Правительства РФ от 3 апреля 2020 г. №441 «Об особенностях обращения лекарственных препаратов для медицинского применения, которые предназначены для применения в условиях угрозы возникновения, возникновения и ликвидации чрезвычайной ситуации и для организации оказания медицинской помощи лицам, пострадавшим в результате чрезвычайных ситуаций, предупреждения чрезвычайных ситуаций, профилактики и лечения заболеваний, представляющих опасность для окружающих, заболеваний и поражений, полученных в результате воздействия неблагоприятных химических, биологических, радиационных факторов». Режим доступа http://government.ru/docs/39399/ Ссылка активна на 12.07.2023 [Decree of the Government of the Russian Federation of April 3, 2020 №441 “On the peculiarities of the circulation of medicinal products for medical use, which are intended for use in conditions of the threat of the emergence, occurrence and liquidation of an emergency and for organizing the provision of medical care to persons affected by emergencies, prevention emergency situations, prevention and treatment of diseases that pose a danger to others, diseases and injuries resulting from exposure to adverse chemical, biological, radiation factors”. Available at: http://government.ru/docs/39399/ Accessed: 12.07.2023 (in Russian)].
57. Постановление Правительства РФ от 28 августа 2014 г. №871 «Об утверждении Правил формирования перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи». Режим доступа: http://government.ru/docs/all/131319/ Ссылка активна на 12.07.2023 [Decree of the Government of the Russian Federation of August 28, 2014 №871 “On approval of the Rules for the formation of lists of drugs for medical use and the minimum range of drugs necessary for the provision of medical care”. Available at: http://government.ru/docs/all/131319/ Accessed: 12.07.2023 (in Russian)].
________________________________________________
2. Stopcoronavirus.rf – official Internet resource for informing the population about coronavirus (COVID-19). Available at: https://стопкоронавирус.рф/ Accessed: 12.07.2023 (in Russian).
3. Information for Persons Who Are Immunocompromised Regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages. Available at: https://www.cdc.gov/mmwr/volumes/72/wr/mm7205e3.htm. Accessed: 12.07.2023.
4. Nussenblatt V, Roder AE, Das S, et al. Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion. medRxiv [Preprint]. 2021:2021.10.02.21264267. DOI:10.1101/2021.10.02.21264267
5. Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592(7853):277-82. DOI:10.1038/s41586-021-03291-y
6. Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. New Engl J Med. 2021;385(13):1244-6. DOI:10.1056/NEJMc2111462
7. Cheung MW, Dayam RM, Shapiro JR, et al. Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in immunocompromised adult patients. J Immunol. 2023;211(3):351-64. DOI:10.4049/jimmunol.2300190
8. Turtle L, Thorpe M, Drake TM, et al. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the who ISARIC CCP-UK prospective cohort study. PLoS Med. 2023;20(1):e1004086. DOI:10.1371/journal.pmed.1004086
9. Singson JRC, Kirley PD, Pham H, et al. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19 – COVID-NET, 10 states, March 2020 – February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(27):878. DOI:10.15585/mmwr.mm7127a3
10. Brosh-Nissimov T, Hussein K, Wiener-Well Y, et al. Hospitalized patients with severe coronavirus disease 2019 during the omicron wave in Israel: Benefits of a fourth vaccine dose. Clin Infect Dis. 2023;76(3):e234-9. DOI:10.1093/cid/ciac501
11. All-Russian Union of Patients. Analysis of the impact of coronavirus infection on immunocompromised people. Available at: https://vspru.ru/news/2023/04/10042023-gruppa-riska-silno-riskuet. Accessed: 09.06.2023 (in Russian).
12. Nasonov EL, Lila AM, Mazurov VI, et al. Coronavirus disease 2019 (COVID-19) and immunoinflammatory rheumatic diseases. Recommendations of the All-Russian public organization “Association of Rheumatologists of Russia”. Scientific and Practical Rheumatology. 2021;59(3):239-54 (in Russian). DOI:10.47360/1995-4484-2021-239-254
13. Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(10):1255-65. DOI:10.1136/annrheumdis-2021-221244
14. Saleem B, Ross RL, Bissell LA, et al. Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses. RMD Open. 2022;8(1):e002050. DOI:10.1136/rmdopen-2021-002050
15. Khemiri H, Ayouni K, Triki H, et al. SARS-CoV-2 infection in pediatric population before and during the Delta (B. 1.617. 2) and Omicron (B. 1.1. 529) variants era. Virol J.
2022;19(1):1-16. DOI:10.1186/s12985-022-01873-4
16. Leidman E, Duca LM, Omura JD, et al. COVID-19 trends among persons aged 0–24 years – United States, March 1 – December 12, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(3):88. DOI:10.15585/mmwr.mm7003e1
17. Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr. 2021;180(7):2019-34. DOI:10.1007/s00431-021-03993-5
18. Brough HA, Kalayci O, Sediva A, et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – the 2020 COVID-19 pandemic: a statement from the EAACI-section on pediatrics. Pediatr Allergy Immunol. 2020;31(5):442-8. DOI:10.1111/pai.13262
19. Jansen MHA, Rondaan C, Legger GE, et al. EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Ann Rheum Dis. 2023;82(1):35-47. DOI:10.1136/annrheumdis-2022-222574
20. Kato M. New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors. Immunol Med. 2020;43(2):72-8. DOI:10.1080/25785826.2020.1751908
21. Kriulin IA, Alekseeva EI, Dvoryakovskaya TM, et al. Hemophagocytic syndrome: mechanisms of development, clinical manifestations, therapeutic technologies. Clinical Practice in Pediatrics. 2021;16(6):94-102 (in Russian). DOI:10.20953/1817-7646-2021-6-94-102
22. Shilov EM, Esayan AM, Shilova MM, et al. Possible structure of stages of chronic kidney disease in the Russian Federation. Clinical Nephrology. 2021;4:6-7 (in Russian). DOI:10.18565/nephrology.2021.4.6-7
23. Shilov EM, Shilova MM, Rumyantseva EI, et al. The state of the nephrological service in the Russian Federation: renal replacement therapy in the period from 2017 to 2021. Clinical Nephrology. 2021;1:6‑15 (in Russian). DOI:10.18565/nephrology.2022.1.6-15
24. Kotenko ON, Vasina NV, Marchenkova LV, et al. State of replacement therapy for chronic renal failure in Moscow in 2015–2020. Clinical Nephrology. 2021;1:13-9 (in Russian). DOI:10.18565/nephrology.2021.1.13-19
25. Batyushin MM, Trubnikova MA, Tarlovskaya EI, et al. Influence of kidney damage on the course and prognosis of COVID-19 infection according to the international registry “Analysis of the dynamics of comorbid diseases in patients who have undergone SARS-CoV-2 infection”. Archive of Internal Medicine. 2023;13(2):116-28 (in Russian).
DOI:10.20514/2226-6704-2023-13-2-116-128
26. Shilov EM, Shilova MM, Rumyantseva EI, et al. Epidemiology of COVID-19 in Patients on Renal Replacement Therapy in the Russian Federation in 2021 (Summary). Clinical Nephrology. 2022;2:6-8 (in Russian). DOI:10.18565/nephrology.2022.2.6-8
27. Shutov EV, Bol'shakov SA, Kotlyarova GV, et al. Evaluation of the humoral response to vaccination with Gam-Covid-Vak (Sputnik V) against COVID-19 in patients on ambulatory dialysis and peritoneal dialysis. Clinical Nephrology. 2022;3:8 (in Russian). DOI:10.18565/nephrology.2022.3.8-14
28. Kim IG, Novikova LI, Frolova NF, et al. Features of COVID-19 vaccine prevention in kidney transplant recipients. Nephrology and Dialysis. 2022;24(4):884-91 (in Russian). DOI:10.28996/2618-9801-2022-4-884-891
29. Frolova NF, Kim IG, Ushakova AI, et al. COVID-19 in patients receiving treatment with program hemodialysis. Infectious Diseases: News, Opinions, Training. 2021;10(1):14‑23 (in Russian). DOI:10.33029/2305-3496-2021-10-1-14-23
30. Zubkin ML, Kim IG, Frolova NF, et al. Novel coronavirus infection and hemodialysis: course and predictors of adverse outcome. Nephrology and Dialysis. 2021;23(4):489-98 (in Russian). DOI:10.28996/2618-9801-2021-4-489-498
31. Kim IG, Artyukhina LYu, Frolova NF, et al. SARS-CoV-2 infection in kidney transplant recipients. Nephrology and Dialysis. 2021;23(2):174-84 (in Russian).
DOI:10.28996/2618-9801-2021-2-174-184
32. Kim I, Frolova N, Artyukhina L, et al. MO934 COVID-19 in renal transplant recipients (RTR). Nephrol Dial Transplant. 2021;36(Suppl. 1):gfab110.0013.
DOI:10.1093/ndt/gfab110.0013
33. Zubkin ML, Frolova NF, Kim IG, et al. COVID-19 in haemodialysis patients: result analysis of the first year of the pandemic. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(11):1325-33 (in Russian). DOI:10.26442/00403660.2021.11.201215
34. Aleshina OA, Zakurdaeva K, Vasileva AN, et al. Clinical Outcomes in Patients With COVID-19 and Hematologic Disease. Clin Lymphoma Myeloma Leuk. 2023;23(8):589-98. DOI:10.1016/j.clml.2023.04.002
35. Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. DOI:10.1186/s13045-021-01177-0
36. Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022;140(3):236-52. DOI:10.1182/blood.2021012251
37. Pagano L, Salmanton-García J, Marchesi F, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood. 2022;140(26):2773-87. DOI:10.1182/blood.2022017257
38. Sahota A, Tien A, Yao J, et al. Incidence, risk factors, and outcomes of COVID-19 infection in a large cohort of solid organ transplant recipients. Transplantation. 2022;106(12):2426. DOI:10.1097/TP.0000000000004371
39. Gautier SV, Shevchenko AO, Tsirulnikova OM. Features of the clinical course of coronavirus infection COVID-19 in recipients of the heart, kidney, liver: the first results of the national multicenter observational study “ROCCOR-recipient”. Bulletin of Transplantology and Artificial Organs. 2020;22(3):8-17 (in Russian). DOI:10.15825/1995-1191-2020-3-8-17
40. Ma BM, Tam AR, Chan KW, et al. Immunogenicity and safety of COVID-19 vaccines in patients receiving renal replacement therapy: a systematic review and meta-analysis. Front Med (Lausanne). 2022;9:827859. DOI:10.3389/fmed.2022.827859
41. Sanders JF, Bemelman FJ, Messchendorp AL, et al. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2022;106(4):821. DOI:10.1097/TP.0000000000003983
42. Roppelt AA, Lebedkina MS, Chernov AA, et al. Pre-exposure prophylaxis of novel coronavirus infection COVID-19 with thixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(1):78‑84 (in Russian). DOI:10.26442/00403660.2023.01.202088
43. Milota T, Sobotková M, Smetanova J, et al. Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity – Results From a Multicenter Nationwide Study. Front Immunol. 2022;13:835770. DOI:10.3389/fimmu.2022.835770
44. Durkee-Shock JR, Keller MD. Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity. Ann Allergy Asthma Immunol. 2022;129(5):562-71.e1. DOI:10.1016/j.anai.2022.06.009
45. On Amendments to the Order of the Ministry of Health of the Russian Federation from December 6, 2021 №1122n. Available at: https://regulation.gov.ru/Regulation/Npa/PublicView?npaID=140206. Accessed: 22.08.2023 (in Russian).
46. Interim guidelines for the prevention, diagnosis and treatment of a new coronavirus infection (COVID-19), version 17. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/252/original/%D0%92%D0%9C%D0%A0.... Accessed: 12.07.2023 (in Russian).
47. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab – cilgavimab) for prevention of COVID-19. New Engl J Med. 2022;386(23):2188-200. DOI:10.1056/NEJMoa2116620
48. Suribhatla R, Starkey T, Ionescu MC, et al. Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients. medRxiv. 2022:2022-11. DOI:10.1111/bjh.18782
49. Kokina MYu, Fomina DS, Lebedkina MS. Efficacy and safety of using a two-component preparation of monoclonal antibodies to SARS-CoV-2 (tixagevimab + cilgavimab) for pre-exposure prophylaxis of a new coronavirus infection in immunocompromised pediatric patients with rheumatic diseases. Preliminary results of the first prospective observational cohort study in the Russian Federation. Questions of Practical Pediatrics. 2023;18(1):16-26 (in Russian). DOI:10.20953/1817-7646-2023-1-16-26
50. Valiakhmetova ChKh, Siraeva EI. Modern opportunities to improve the results of prevention and course of COVID-19 infection in patients with lymphoproliferative diseases (regional analysis). Oncohematology. 2023;18(2):68-73 (in Russian). DOI:10.17650/1818-8346-2023-18-2-68-73
51. Beketova TV, Levina NO, Dubinskaya MV. Experience with thixagevimab and cilgavimab (Evusheld) in 86 rheumatic patients receiving anti-B-cell therapy with rituximab. Scientific and Practical Rheumatology. 2023;61(2):158-64 (in Russian). DOI:10.47360/1995-4484-2023-158-164
52. Valiakhmetova ChKh, Siraeva ER, Izmailov AA. Effective prevention of COVID-19 infection in cancer patients receiving antitumor drug therapy (regional analysis). Modern Oncology. 2023;25(1):111-14 (in Russian). DOI:10.26442/18151434.2023.1.202170
53. Antonov VN, Ignatova GL. Efficacy and safety of immunization of patients with chronic obstructive pulmonary disease with monoclonal antibodies. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(3):243-7 (in Russian). DOI:10.26442/00403660.2023.03.202146
54. Balabokhina MV, Nazarova OI, Skotnikova EA, et al. Experience with the use of thixagevimab/cilgavimab for pre-exposure prophylaxis of COVID-19 in patients with HIV infection in the Omsk region. Lechaschi Vrach. 2023;3(26):48-51 (in Russian). DOI:10.51793/OS.2023.26.3.008
55. Aleshina (Gavrilina) O, Zhabrailova A, Troistskaya V. P1574: Efficacy and safety of tixagevimab and cilgavimab (Evusheld) in patients with hematological malignancies. Hemasphere. 2023;7(Suppl.):e68761f9. DOI:10.1097/01.HS9.0000973172.68761.f9
56. Decree of the Government of the Russian Federation of April 3, 2020 №441 “On the peculiarities of the circulation of medicinal products for medical use, which are intended for use in conditions of the threat of the emergence, occurrence and liquidation of an emergency and for organizing the provision of medical care to persons affected by emergencies, prevention emergency situations, prevention and treatment of diseases that pose a danger to others, diseases and injuries resulting from exposure to adverse chemical, biological, radiation factors”. Available at: http://government.ru/docs/39399/ Accessed: 12.07.2023 (in Russian).
57. Decree of the Government of the Russian Federation of August 28, 2014 №871 “On approval of the Rules for the formation of lists of drugs for medical use and the minimum range of drugs necessary for the provision of medical care”. Available at: http://government.ru/docs/all/131319/ Accessed: 12.07.2023 (in Russian).
Авторы
Экспертный совет
С.Н. Авдеев*1, В.П. Чуланов1,2, Е.И. Алексеева1,3, О.А. Алешина4, А.В. Березников5,6, О.Н. Котенко7,8, А.М. Лила9,10, З.Ю. Мутовина7,11, Е.Н. Паровичникова4, Д.С. Фомина1,7, Н.Ф. Фролова7,12, А.О. Шевченко1,8,13
1ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных болезней» Минздрава России, Москва, Россия;
3ФГАУ «Национальный медицинский исследовательский центр здоровья детей» Минздрава России, Москва, Россия;
4ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия;
5ООО «АльфаСтрахование-ОМС», Москва, Россия;
6ФГБОУ ВО «РОСБИОТЕХ», Москва, Россия;
7ГБУЗ «Городская клиническая больница №52» Департамента здравоохранения г. Москвы, Москва, Россия;
8ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
9ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
10ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
11ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РФ, Москва, Россия;
12ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия;
13ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов им. акад. В.И. Шумакова» Минздрава России, Москва, Россия
*serg_avdeev@list.ru
Председатели совета: С.Н. Авдеев, В.П. Чуланов
Sergey N. Avdeev*1, Vladimir P. Chulanov1,2, Ekaterina I. Alexeeva1,3, Olga A. Aleshina4, Aleksey V. Bereznikov5,6, Oleg N. Kotenko7,8, Aleksander M. Lila9,10, Zinaida Yu. Mutovina7,11, Elena N. Parovichnikova4, Daria S. Fomina1,7, Nadiya F. Frolova7,12, Aleksey O. Shevchenko1,8,13
1Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2National Medical Research Center for Phthisiopulmonology and Infectious Diseases, Moscow, Russia;
3National Medical Research Center for Children's Health, Moscow, Russia;
4National Medical Research Center for Hematology, Moscow, Russia;
5AlfaStrakhovanie-OMS LLC, Moscow, Russia;
6ROSBIOTECH University, Moscow, Russia;
7City Clinical Hospital №52, Moscow, Russia;
8Pirogov Russian National Research Medical University, Moscow, Russia;
9Nasonova Research Institute of Rheumatology, Moscow, Russia;
10Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
11Central State Medical Academy of the Administrative Department of the President of the Russian Federation, Moscow, Russia;
12Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia;
13Shumakov National Medical Research Center for Transplantology and Artificial Organs, Moscow, Russia
*serg_avdeev@list.ru
С.Н. Авдеев*1, В.П. Чуланов1,2, Е.И. Алексеева1,3, О.А. Алешина4, А.В. Березников5,6, О.Н. Котенко7,8, А.М. Лила9,10, З.Ю. Мутовина7,11, Е.Н. Паровичникова4, Д.С. Фомина1,7, Н.Ф. Фролова7,12, А.О. Шевченко1,8,13
1ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных болезней» Минздрава России, Москва, Россия;
3ФГАУ «Национальный медицинский исследовательский центр здоровья детей» Минздрава России, Москва, Россия;
4ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия;
5ООО «АльфаСтрахование-ОМС», Москва, Россия;
6ФГБОУ ВО «РОСБИОТЕХ», Москва, Россия;
7ГБУЗ «Городская клиническая больница №52» Департамента здравоохранения г. Москвы, Москва, Россия;
8ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
9ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
10ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
11ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РФ, Москва, Россия;
12ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия;
13ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов им. акад. В.И. Шумакова» Минздрава России, Москва, Россия
*serg_avdeev@list.ru
Председатели совета: С.Н. Авдеев, В.П. Чуланов
________________________________________________
Sergey N. Avdeev*1, Vladimir P. Chulanov1,2, Ekaterina I. Alexeeva1,3, Olga A. Aleshina4, Aleksey V. Bereznikov5,6, Oleg N. Kotenko7,8, Aleksander M. Lila9,10, Zinaida Yu. Mutovina7,11, Elena N. Parovichnikova4, Daria S. Fomina1,7, Nadiya F. Frolova7,12, Aleksey O. Shevchenko1,8,13
1Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2National Medical Research Center for Phthisiopulmonology and Infectious Diseases, Moscow, Russia;
3National Medical Research Center for Children's Health, Moscow, Russia;
4National Medical Research Center for Hematology, Moscow, Russia;
5AlfaStrakhovanie-OMS LLC, Moscow, Russia;
6ROSBIOTECH University, Moscow, Russia;
7City Clinical Hospital №52, Moscow, Russia;
8Pirogov Russian National Research Medical University, Moscow, Russia;
9Nasonova Research Institute of Rheumatology, Moscow, Russia;
10Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
11Central State Medical Academy of the Administrative Department of the President of the Russian Federation, Moscow, Russia;
12Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia;
13Shumakov National Medical Research Center for Transplantology and Artificial Organs, Moscow, Russia
*serg_avdeev@list.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.